BridgeBio Pharma Inc (OQ:BBIO)

Apr 10, 2024 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the compensation committee of BridgeBio’s board of...
Apr 07, 2024 01:15 pm ET
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardi
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented results from the exploratory CMR imaging substudy of ATTRibute-CM, its Phase...
Mar 20, 2024 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of BridgeBio’s board of...
Mar 05, 2024 11:53 pm ET
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its...
Mar 04, 2024 04:17 pm ET
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common...
Mar 04, 2024 02:30 am ET
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million...
Feb 22, 2024 07:30 am ET
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Presented additional data from ATTRibute-CM at the American Heart Association Scientific Sessions, demonstrating separation at Month 3 of the placebo and acoramidis time-to-first-event Kaplan-Meier curves for a composite of all-cause mortality (ACM)...
Feb 07, 2024 07:34 am ET
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Kyowa Kirin Co., Ltd (TSE:4151) (Kyowa Kirin) today announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialize...
Feb 06, 2024 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the compensation committee of BridgeBio’s board...
Feb 05, 2024 07:30 am ET
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the...
Feb 02, 2024 07:00 am ET
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today shared positive results from the Japan Phase III trial of acoramidis in adults with...
Jan 30, 2024 06:00 am ET
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. 
Jan 18, 2024 07:00 am ET
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced strategic financing from Blue Owl Capital (Blue Owl) and Canada Pension Plan...
Jan 10, 2024 05:15 pm ET
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of
Acoramidis demonstrated an observed 30-month survival rate of 80.7% in the treatment arm of ATTRibute-CM; recent data from the U.S. Social Security Administration estimated 30-month survival at 85% in an age-matched cohort of the general population;...
Jan 10, 2024 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on January 08, 2024, the compensation committee of BridgeBio’s board of...
Jan 03, 2024 04:30 pm ET
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 42nd Annual J.P....
Jan 03, 2024 07:30 am ET
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced that the United States Food and Drug Administration (FDA) has cleared the...
Dec 13, 2023 07:30 am ET
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first child has been dosed in PROPEL 3, a Phase 3 clinical trial studying the efficacy...
Dec 08, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the compensation committee of BridgeBio’s board...
Dec 05, 2023 07:44 am ET
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (A
In ATTRibute-CM, acoramidis treatment demonstrated an 81% absolute survival rate and a 0.29 observed mean annual CVH frequency, as well as improvements for a large proportion of patients on laboratory and functional measures - ATTRibute-CM results...
Nov 12, 2023 10:30 am ET
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
The placebo and acoramidis time-to-first event Kaplan-Meier (K-M) curves for a composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH) separated beginning at Month 3, representing the most rapid & sustained clinical...
Nov 09, 2023 07:30 am ET
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessi
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its...
Nov 08, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on November 07, 2023, the compensation committee of BridgeBio’s board...
Nov 02, 2023 07:30 am ET
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2023, and...
Oct 11, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on October 06, 2023, the compensation committee of BridgeBio’s board of...
Oct 10, 2023 07:30 am ET
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
No serious adverse events were reported with encaleret and no treatment discontinuations or study withdrawals occurred during the trial - The Phase 3 CALIBRATE trial of encaleret in patients with ADH1 is ongoing in six countries with topline data...
Oct 09, 2023 07:30 am ET
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Mu
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, shared new long-term data from its Phase 2 trial in patients with limb-girdle muscular...
Oct 03, 2023 07:31 am ET
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and
Oct 03, 2023 07:30 am ET
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
BridgeBio Pharma, Inc. (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to...
Sep 25, 2023 07:30 am ET
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into a securities purchase agreement with certain existing and new accredited...
Sep 08, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on September 06, 2023, the compensation committee of BridgeBio’s board...
Sep 07, 2023 07:30 am ET
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st...
Sep 06, 2023 07:30 am ET
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
FDA and EMA alignment was reached on the adequacy of a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial for infigratinib to support a marketing application for the treatment of children with achondroplasia - The primary endpoint...
Aug 27, 2023 06:15 am ET
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2
The 0.29 mean annual CVH rate on acoramidis approaches the annual hospitalization rate observed in the broader US Medicare population (~0.26) - Assessment of measures of disease progression in the trial suggest that on acoramidis, 45% of subjects...
Aug 24, 2023 04:01 pm ET
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in...
Aug 04, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on August 02, 2023, the compensation committee of BridgeBio’s board of...
Aug 03, 2023 07:30 am ET
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2023 and provided an...
Jul 31, 2023 07:30 am ET
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that, based on discussions with the U.S. Food and Drug Administration (FDA),...
Jul 18, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on July 10, 2023, the compensation committee of BridgeBio’s board of...
Jul 17, 2023 09:31 am ET
Thinking about trading options or stock in Coinbase Global, Trade Desk, NVIDIA, Advanced Micro Devices, or BridgeBio Pharma?
NEW YORK, July 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COIN, TTD, NVDA, AMD, and BBIO.
Jul 17, 2023 07:00 am ET
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
58% of ties in Finkelstein-Schoenfeld (F-S) primary analysis broken by all-cause mortality and frequency of cardiovascular-related hospitalization; statistical significance also achieved on an F-S test with those two parameters alone (p=0.0182) -...
Jul 14, 2023 04:01 pm ET
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET...
Jul 12, 2023 04:31 pm ET
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
Burjeel Holdings, one of the largest healthcare providers in the MENA region, and BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, have announced a new project to revolutionize the field...
Jun 20, 2023 07:30 am ET
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, presented updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the...
Jun 13, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on June 11, 2023, the compensation committee of BridgeBio’s board of...
Jun 08, 2023 07:30 am ET
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial...
May 22, 2023 07:30 am ET
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Mee
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, presented promising positive data from six participants dosed in CANaspire, its Phase 1/2...
May 15, 2023 07:30 am ET
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812,...
May 11, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on May 9, 2023, the compensation committee of BridgeBio’s board of...
May 04, 2023 07:30 am ET
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2023 and provided an...
Apr 27, 2023 07:30 am ET
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America...
Apr 19, 2023 09:46 am ET
Thinking about buying stock in Western Alliance Bancorp, Genprex, Windtree Therapeutics, BridgeBio Pharma, or PacWest Bancorp?
NEW YORK, April 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WAL, GNPX, WINT, BBIO, and PACW.
Apr 11, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2023, the compensation committee of BridgeBio’s board of...
Apr 07, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of...
Mar 23, 2023 07:30 am ET
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
BridgeBio Pharma, Inc., (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2...
Mar 21, 2023 07:30 am ET
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the Company’s novel validated muscle tissue-based bioassay, which measures...
Mar 17, 2023 07:30 am ET
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that preliminary data on the Company’s muscle tissue-based bioassay...
Mar 08, 2023 07:00 am ET
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 7, 2023 of an underwritten public offering of 8,823,530 shares of its...
Mar 06, 2023 04:05 pm ET
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $150 million of shares of its common...
Mar 06, 2023 07:00 am ET
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Even
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive results from PROPEL2, a Phase 2 trial of the investigational therapy infigratinib in...
Mar 03, 2023 07:30 am ET
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, March 6 at 7:30 am ET...
Feb 23, 2023 07:30 am ET
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31,...
Feb 17, 2023 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 13, 2023, the compensation committee of BridgeBio’s board...
Feb 13, 2023 07:30 am ET
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host a roundtable discussion on...
Feb 08, 2023 07:30 am ET
BridgeBio Pharma to Participate in February and March Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following...
Jan 04, 2023 07:30 am ET
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P....
Dec 22, 2022 07:30 am ET
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
The primary composite endpoint evaluates the proportion of participants with ADH1 achieving blood and urinary calcium within widely accepted normal ranges - In an ongoing single arm, open-label, Phase 2 safety and efficacy study of patients with...
Nov 09, 2022 07:30 am ET
BridgeBio Pharma to Participate in November Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following...
Nov 03, 2022 07:30 am ET
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Reported updated positive data from its Phase 1/2 trial of BBP-812, an AAV9 gene therapy candidate for the treatment of Canavan disease - Received approval of NULIBRY (fosdenopterin) as a treatment for molybdenum cofactor deficiency (MoCD) Type A...
Oct 17, 2022 12:30 pm ET
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Sympo
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented preclinical data for its two lead RAS programs – a next-generation KRASG12C...
Oct 14, 2022 07:30 am ET
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease in the ratio of glycosylated αDG to total αDG from baseline towards normal levels, suggesting that...
Oct 13, 2022 04:00 pm ET
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented promising pharmacodynamic, tolerability and preliminary functional efficacy...
Oct 11, 2022 07:30 am ET
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
BridgeBio Pharma, Inc., (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its Phase 1/2...
Oct 07, 2022 07:30 am ET
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that preclinical data for its two lead RAS programs – a next-generation KRAS...
Sep 20, 2022 07:30 am ET
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing...
Sep 06, 2022 07:30 am ET
BridgeBio Pharma to Participate in September Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following...
Aug 18, 2022 07:30 am ET
BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in its Phase 1 clinical trial of...
Aug 10, 2022 07:30 am ET
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
NULIBRY was approved by the U.S. Food and Drug Administration (FDA) in February 2021 and was BridgeBio’s first approved therapy; Medison acquired commercialization rights to NULIBRY in Israel in December 2019; Sentynl acquired global rights to...
Aug 04, 2022 07:30 am ET
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
Received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union (EU) for NULIBRY® (fosdenopterin) for the treatment of molybdenum cofactor deficiency (MoCD) Type A - Entered into...
Jul 26, 2022 09:31 am ET
Thinking about buying stock in Clene, BridgeBio Pharma, Geovax Labs, Southwestern Energy, or Comstock Resources?
NEW YORK, July 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLNN, BBIO, GOVX, SWN, and CRK.
Jul 26, 2022 07:30 am ET
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years o
Infigratinib is the only known oral product candidate currently under clinical investigation for achondroplasia, with granted and filed patent applications expiring as late as 2041 PALO ALTO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- BridgeBio...
Jul 25, 2022 07:30 am ET
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing...
Jul 25, 2022 07:30 am ET
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural history study
Jul 21, 2022 07:30 am ET
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into...
Jul 21, 2022 07:30 am ET
BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced its founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEnginuity Hub. Bakar Labs...
Jun 27, 2022 07:30 am ET
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Form
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive Phase 1 data for BBP-711 in healthy volunteers, supporting the development of the investigational...
Jun 22, 2022 07:30 am ET
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced promising pharmacodynamic data from the first two participants dosed in CANaspire, its Phase 1/2 clinical...
Jun 17, 2022 06:59 am ET
Stephen Bardin to Join atai Life Sciences as CFO Designate
atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today that Stephen Bardin, currently Senior Vice President of...
Jun 13, 2022 08:00 am ET
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive Phase 2b data of encaleret in patients with autosomal dominant...
Jun 10, 2022 07:30 am ET
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed venolymphatic...
Jun 09, 2022 07:30 am ET
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that 24-week Phase 2b data of encaleret in patients with autosomal dominant...
Jun 06, 2022 07:30 am ET
BridgeBio Pharma to Participate in June Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following...
May 26, 2022 01:00 pm ET
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced interim Phase 1 data from healthy volunteers, supporting the development of...
May 20, 2022 07:30 am ET
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an...
May 17, 2022 07:30 am ET
BridgeBio Pharma to Participate in May Investor Events
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following...
May 13, 2022 07:30 am ET
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its PRV...
May 12, 2022 07:30 am ET
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today an exclusive license with Bristol Myers Squibb to develop and commercialize BBP-398, a...
May 10, 2022 04:30 pm ET
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in the Bank of America...
May 05, 2022 07:30 am ET
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2022 and provided an...
Apr 03, 2022 08:36 am ET
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Acoramidis remained generally well-tolerated with no safety signals of clinical concern identified - Topline data from ongoing Phase 3 trial of acoramidis in ATTR-CM (ATTRibute-CM) are expected in mid-2023 PALO ALTO, Calif., April 03, 2022...
Mar 28, 2022 07:30 am ET
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual S
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that updated data from its ongoing Phase 2 open-label extension (OLE) study...
Mar 14, 2022 07:30 am ET
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and its affiliate company ML Bio Solutions, today announced positive data from the Phase 2...
Mar 11, 2022 07:30 am ET
BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor call on March 14, 2022, at 8:00 AM ET to...
Mar 08, 2022 07:30 am ET
BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing...
Feb 24, 2022 07:30 am ET
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter ended December 31, 2021 and provided...
Feb 01, 2022 06:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jan 27, 2022 08:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 27, 2022 07:30 am ET
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in ADventure, its Phase 1/2 clinical...
Jan 23, 2022 01:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jan 17, 2022 07:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, Jan. 17, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 17, 2022 06:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, Jan. 17, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 13, 2022 09:54 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jan 13, 2022 07:30 am ET
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of...
Jan 06, 2022 05:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 03, 2022 08:31 am ET
Thinking about buying stock in Armstrong Flooring, Ensysce Biosciences, BridgeBio Pharma, Xpeng, or Li Auto?
NEW YORK, Jan. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFI, ENSC, BBIO, XPEV, and LI.
Dec 30, 2021 09:45 am ET
Thinking about buying stock in CooTek, Puxin, DiDi Global, IQIYI, or BridgeBio Pharma?
NEW YORK, Dec. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTK, NEW, DIDI, IQ, and BBIO.
Dec 29, 2021 09:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 28, 2021 06:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Dec 28, 2021 09:45 am ET
Thinking about buying stock in Reliance Global, LiveOne, BridgeBio Pharma, Flotek Industries, or Nikola Corp?
NEW YORK, Dec. 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RELI, LVO, BBIO, FTK, and NKLA.
Dec 27, 2021 09:45 am ET
Thinking about buying stock in Biolase, BridgeBio Pharma, American Airlines, Expro Group, or Genocea Biosciences?
NEW YORK, Dec. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOL, BBIO, AAL, XPRO, and GNCA.
Dec 27, 2021 07:00 am ET
BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study
- ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and...
Dec 10, 2021 07:30 am ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new...
Nov 19, 2021 07:30 am ET
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets...
Nov 18, 2021 07:30 am ET
BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has executed a definitive credit facility agreement with a syndicate of...
Nov 04, 2021 07:30 am ET
BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update
PALO ALTO, Calif., Nov. 4, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2021 and provided an update on the Company's operations.
Nov 03, 2021 07:30 am ET
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
PALO ALTO, Calif., Nov. 3, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for the treatment of Canavan disease. Canavan disease is an ultra-rare and fatal disease that affects approximately 1,000 children in the United States and European Union. There are currently no approved therapies for the condition.
Oct 29, 2021 07:30 am ET
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
PALO ALTO, Calif., Oct. 29, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia University and Mount Sinai (Icahn Mount Sinai) to translate cutting-edge research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
Oct 25, 2021 07:30 am ET
BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valan
Oct 12, 2021 07:30 am ET
BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers
PALO ALTO, Calif., Oct. 12, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing meaningful progress in its KRAS cancer portfolio, new programs in gene therapy, and advancements in cardiorenal and early-stage Mendelian programs at its second annual R&D Day today. BridgeBio will also discuss how it is broadening the scope of its R&D engine with the launch of its new early-stage research institute, BridgeBioX.
Oct 07, 2021 09:00 am ET
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small
PALO ALTO, Calif., Oct. 7, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced preclinical findings for its SHP2 inhibitor, BBP-398, in non-small cell lung cancer (NSCLC). The results are featured in a poster presentation titled 'BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and EGFRmut inhibitors' at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place virtu
Oct 06, 2021 07:30 am ET
BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021
PALO ALTO, Calif., Oct. 6, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET.
Oct 01, 2021 05:00 pm ET
BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants
PALO ALTO, Calif., Oct. 1, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced updated results from its ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1). Within five days of individualized dose titration in 13 participants, encaleret normalized mean blood calcium levels and 24 hour urine calcium excreti
Sep 15, 2021 07:30 am ET
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
PALO ALTO, Calif., Sept. 15, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the United States Food and Drug Administration (FDA) granted Fast Track designation for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). The FDA grants development programs Fast Track designation to help drive the development and expedite its rev
Sep 08, 2021 05:00 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on September 2, 2021, the compensation committee of BridgeBio's board of directors granted 29 new employees restricted stock units for an aggregate of 61,210 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan (the Plan).
Aug 25, 2021 07:00 am ET
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors
LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification and other advanced solid tumors with FGFR genomic alterations.
Aug 18, 2021 07:30 am ET
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors
PALO ALTO, Calif., Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that it has added three new independent directors to its board: Fred Hassan, a pharmaceutical and financial industry giant who is the former CEO of Schering-Plough and former chairman of Bausch & Lomb; Andrea Ellis, a consumer technology innovator and the chief financial officer of Lime; and Douglas Da
Aug 05, 2021 07:30 am ET
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update
PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the Company's operations.
Aug 04, 2021 07:01 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Aug. 4, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on August 3, 2021, the compensation committee of BridgeBio's board of directors granted 17 new employees restricted stock units for an aggregate of 21,414 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan (the Plan).
Jul 27, 2021 07:30 am ET
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with
PALO ALTO, Calif., July 27, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with OPDIVO® (nivolumab) in patients with advanced solid tumors with KRAS mutations with the hope of providing an effective new treatme
Jul 12, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 12, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on July 1, 2021, the compensation committee of BridgeBio's board of directors granted 20 new employees restricted stock units for an aggregate of 26,761 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan (the Plan).
Jul 08, 2021 07:30 am ET
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
PALO ALTO, Calif., July 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
Jun 28, 2021 07:10 pm ET
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of...
Jun 14, 2021 04:35 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that...
Jun 01, 2021 07:30 am ET
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that...
Jun 01, 2021 07:00 am ET
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved TRUSELTIQ™ (infigratinib) under the accelerated approval program for the treatment of patients with previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. TRUSELTIQ is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR. In the pivotal trial of patients with advanced, unresectable CCA, an aggressive malignancy with poor prognosis, T
May 28, 2021 02:30 pm ET
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has approved TRUSELTIQ™ (infigratinib) under the accelerated approval program for...
May 14, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021, the compensation committee of BridgeBio’s board of directors granted 27 new employees restricted...
May 14, 2021 07:30 am ET
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that...
May 06, 2021 07:30 am ET
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic...
Apr 13, 2021 07:45 am ET
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a...
Apr 13, 2021 07:42 am ET
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and...
Apr 13, 2021 07:40 am ET
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers. “We are honored to begin...
Apr 13, 2021 07:37 am ET
BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases
BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven...
Apr 13, 2021 07:35 am ET
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments...
Apr 13, 2021 07:32 am ET
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in glycomics into potential treatments for...
Apr 13, 2021 07:30 am ET
BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients
BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines for patients. “Brown University is a leader...
Apr 06, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on April 5, 2021, the compensation committee of BridgeBio’s board of directors granted 19 new employees restricted...
Mar 31, 2021 07:30 am ET
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced a global collaboration and licensing agreement (the “Agreement”) to further develop and commercialize QED Therapeutics’ FGFR1-3...
Mar 20, 2021 11:00 am ET
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced early...
Mar 02, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio’s board of directors granted 17 new employees restricted...
Feb 28, 2021 08:00 am ET
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc. (Origin) today announced the U.S. Food and Drug Administration (FDA) has approved NULIBRY™ (fosdenopterin) for Injection as the first therapy to reduce the...
Feb 25, 2021 07:30 am ET
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic...
Feb 24, 2021 04:01 pm ET
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that...
Feb 19, 2021 07:30 am ET
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML...
Feb 12, 2021 08:00 am ET
BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per share of $62.50 by selling stockholder KKR Genetic Disorder...
Feb 11, 2021 04:09 pm ET
BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder...
Feb 05, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees...
Feb 02, 2021 07:30 am ET
BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular anomalies, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of...
Jan 26, 2021 08:30 am ET
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already...
Jan 25, 2021 11:04 pm ET
BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to...
Jan 25, 2021 07:00 am ET
BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2029 (the...
Jan 19, 2021 04:01 pm ET
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all...
Jan 13, 2021 04:30 pm ET
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to...
Jan 06, 2021 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio’s board of directors granted six new employees...
Jan 04, 2021 11:42 am ET
EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal...
Jan 04, 2021 07:30 am ET
Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger
BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s...
Dec 23, 2020 07:30 am ET
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases
UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients. “The BridgeBio team is...
Dec 19, 2020 03:11 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - BEAT, SNCA, BBIO, TLRY, NEOS
NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 07, 2020 08:30 am ET
BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Maze Therapeutics today announced the establishment of a joint venture, Contour Therapeutics, focused on transforming and advancing breakthrough precision medicine approaches designed to treat...
Dec 04, 2020 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1, 2020, the compensation committee of BridgeBio’s board of directors granted 15 new employees options...
Dec 04, 2020 10:46 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - WORK, WDR, BBIO, UROV, HDS
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Dec 02, 2020 02:39 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BridgeBio Pharma, Inc. Merger
Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches of fiduciary duties and other violations of law related to BridgeBio’s agreement to merge with Eidos...
Dec 01, 2020 07:30 am ET
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate QED...
Nov 13, 2020 07:30 am ET
BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPK...
Nov 09, 2020 05:15 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos' agreement to be acquired by BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ GS: BBIO).  Under the terms of the agreement, Eidos' shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
Nov 05, 2020 07:30 am ET
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today reported its...
Nov 04, 2020 04:30 pm ET
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 1, 2020, the compensation committee of BridgeBio’s board of directors granted three new employees...
Oct 27, 2020 05:00 pm ET
MERGER ALERT - BSTC, BBIO, and PNM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 27, 2020 07:30 am ET
BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of BBP-589 (also known as PTR-01), an intravenously-administered recombinant collagen 7 (rC7) protein...
Oct 23, 2020 04:35 pm ET
MERGER ALERT - CIT, BBIO, and LSAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 21, 2020 07:30 am ET
BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to advance novel research on genetically driven diseases into therapeutic applications for patients. “We are grateful...
Oct 21, 2020 07:25 am ET
Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease
The Salk Institute and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced a three-year collaboration agreement formed to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications. Under the...
Oct 16, 2020 04:25 pm ET
MERGER ALERT - WTRE, BBIO, and LSAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 16, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 15, 2020 12:06 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), BMC Stock Holdings, Inc., Cellular Biomedicine Group, Inc., and Eidos Therapeutics, Inc.
American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a...
Oct 07, 2020 01:45 pm ET
MERGER ALERT – GHIV, BBIO, and VRTU: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 7, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 05, 2020 09:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Eidos Therapeutics, Inc. Buyout
Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.